| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8780941 | Gynecologic Oncology Reports | 2018 | 4 Pages |
Abstract
Durvalumab plus tremelimumab combination therapy can lead to fulminant immune-mediated myocarditis. This patient's myocarditis was amenable to treatment with high-dose intravenous steroids and mycophenolate.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Syed S. Mahmood, Carol L. Chen, Natalie Shapnik, Udhay Krishnan, Harsimran S. Singh, Vicky Makker,